(Press-News.org) Long Beach, Calif. – May 2, 2024 – Final 12-month data from the EXACT trial demonstrates safety and efficacy results for a vascular endothelial growth factor (VEGF) gene therapy treatment for patients who have advanced coronary artery disease (CAD). The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
CAD, also known as coronary heart disease or ischemic heart disease, affects about 20.5 million U.S. adults – making it the most common type of heart disease in the United States. Often, the first sign of CAD is a heart attack, triggered by a rupture of plaque accumulated in the arteries supplying blood to the heart. Over time, plaque narrows these arteries, blood flow diminishes, leading to angina – a condition characterized by chest pain due to insufficient oxygen-rich blood supply to the heart muscle. In patients with the most severe form, angina can be disabling, and additional medications, procedures or surgery may not be effective. There is a need for therapies for such a serious condition.
The EXACT trial assesses the safety and preliminary efficacy of the gene therapy XC001 in patients with “no option” refractory angina (NORA). The gene vector is designed to more effectively and safely increase the body's own signal for new blood vessel growth. Effectiveness was measured primarily by exercise capacity, degree of impairment of blood flow to the heart, and angina frequency and severity.
Among the 32 patients with NORA, the gene therapy XC001 appeared safe with no serious adverse effects due to the drug. Surgical delivery was generally well-tolerated. Early benefits of XC001 are promising in relation to improvements in exercise duration, decreased symptoms, and improved blood flow in patients’ hearts.
Total exercise duration increased from a mean of 359.9 seconds at baseline to 448.2 at three months, 449.2 at six months, and 477.6 at 12 months. Total myocardial perfusion deficit on positron emission tomography imaging decreased by 10.2% at three months, 14.3% at six months, and 10.2% at 12 months – demonstrating a reduction in impaired blood flood. The time to onset of ST depression during exercise tolerance testing increased by 105.2 at three months, 113.6 at six months, and 103.1 seconds at 12 months. Angina frequency decreased by -7.7 at three months, -6.6 at six months, and -8.8 episodes at 12 months. Angina class improved in 81% of participants at six months.
“Findings from the EXACT trial may not impact clinical practice immediately, but it will lay the groundwork for future studies in this patient population,” said Thomas J. Povsic, MD, Interventional Cardiologist at Duke University Medical Center, and Kenta Nakamura, MD, Interventional Cardiologist at the University of Washington Medical Center, and lead authors of the study. “We hope this will lead to the development of a new treatment for patients with coronary disease or as a frontline therapy for angina, especially for those who are not candidates for additional conventional therapies like PCI or CABG.”
Session Details:
“VEGF Gene Therapy Improves Exercise Time, Ischemia, and Symptoms in Patients with Refractory Angina: Results of the Phase II EXACT Trial”
Thursday, May 2, 2024; 9:31-9:38 AM PT
Long Beach Convention Center, 104A, First Level
###
About Society for Cardiovascular Angiography & Interventions (SCAI)
The Society for Cardiovascular Angiography & Interventions, established in 1978, stands as the primary nonprofit medical society dedicated to representing invasive and interventional cardiology. SCAI's mission is to guide the global interventional cardiovascular community by fostering education, advocacy, research, and upholding standards for quality patient care. For more than 40 years, SCAI has exemplified professional excellence and innovation worldwide, cultivating a reputable community of over 4,500 members committed to advancing medical science and providing life-saving care for individuals, both adults and children, affected by cardiovascular disease. For more information, visit https://scai.org/.
For more information about the SCAI 2024 Scientific Sessions, visit https://scai.org/scai-2024-scientific-sessions. Follow @SCAI on X (formerly Twitter) and on LinkedIn for the latest heart health news and use #SCAI2024 to follow the latest discussions.
END
Long Beach, Calif. – May 2, 2024 – New data demonstrated that a left main (LM) bifurcation-specific novel scoring system (LM V-RESOLVE), based on three simple baseline angiographic findings, could help to rapidly discriminate lesions at risk of side branch (SB) occlusion during LM bifurcation percutaneous coronary intervention (PCI) – reducing risk during the procedure. The results from the prospective trial were presented today as late-breaking science at the Society for Cardiovascular Angiography & Interventions (SCAI) ...
BALTIMORE, May 2, 2024: Bacterial Vaginosis (BV) affects about one-quarter of reproductive-age women and is linked to adverse health outcomes, such as increased HIV risk. Yet for decades, BV treatment in the United States has largely relied on antibiotics, and BV recurrence is common following antibiotic therapy.
Now, two European clinical trials have shown limited success with a different type of medication used to treat BV called dequalinium chloride (DQC). DQC—an antiseptic—has been in use for several decades in countries throughout Europe as an alternative treatment for BV. It is not currently approved by the U.S. ...
Recent reports of NASA’s James Webb Space Telescope finding signs of life on a distant planet understandably sparked excitement. A new study challenges this finding, but also outlines how the telescope might verify the presence of the life-produced gas.
The UC Riverside study, published in the Astrophysical Journal Letters, may be a disappointment to extraterrestrial enthusiasts but does not rule out the near-future possibility of discovery.
In 2023 there were tantalizing reports of a biosignature gas in the atmosphere of planet K2-18b, ...
Long Beach, Calif. – May 2, 2024 – New data demonstrate the superiority of radial arterial access compared to femoral arterial access for coronary interventions. Findings showed radial access was associated with lower rates of in-hospital mortality, major access bleeding, and other major vascular complications compared with femoral access. The late-breaking results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
Historically, femoral arterial access, through the groin, for percutaneous coronary intervention (PCI) was the standard. Radial access, or ...
From medical and dental care to medications, insurance and nursing homes, health-related costs weigh heavily on the minds of older Americans of all backgrounds, a new poll suggests.
Asked to rate their level of concern about 26 different health-related topics for people over 50 in their community, five of the six issues that the most people cited as very concerning involved health costs.
The sixth – financial scams and fraud – also had to do with money.
Those same six topics rose to the top no matter what ...
The alarming rates of biodiversity loss worldwide have made clear that the classical way of governing biodiversity recovery based on protected areas and programmes for the protection of endangered species is not enough. To tackle this, almost 200 countries committed to the active ‘mainstreaming’ or integration of biodiversity targets into policies and plans across relevant sectors. However, research led by Utrecht University and UFZ Helmholz Centre for Environmental Research suggests that this has until now been largely ineffective due to non-binding commitments, ...
As COVID-19 becomes endemic, an important group of people who continue to require vaccination is future birth cohorts of children. Yet, in the face of ever-changing variants, as well as the waning of antibodies with time after each dose, key questions remain: What is the threshold of immune response against SARS-CoV-2 needed to protect against COVID-19 and how many doses of mRNA vaccination are required to reach that threshold?
Researchers answered this question in a joint study conducted by the NUS Yong Loo Lin School of Medicine (NUS Medicine) and Duke-NUS Medical School. With parental consent ...
People with Lower Income and Pre-Existing Conditions at Greater Risk of STEMI in the United States
Women, Black, and Hispanic Patients Up to 25% Less Likely to Receive Treatment for Heart Attacks Compared Men and White Patients
Long Beach, Calif. – May 3, 2024 – New data focusing on heart attack, specifically ST‐segment–elevation myocardial infarction (STEMI), uncovered socio-economic, racial, and gendered disparities associated with greater risk and are less likely to receive certain procedures. The data were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
STEMI, caused by ...
Long Beach, Calif. – May 4, 2024 – A nationwide observational analysis of patients with aortic stenosis (AS) and cardiogenic shock (CS) who underwent transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) determined that patients who underwent TAVR had lower in-hospital complications and resource utilization compared with SAVR. The results were presented today at the Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions.
As many as 300,000 people in the United States are diagnosed with AS every year. It predominantly affects those ...
Hispanic Population Largely Remains Underrepresented in Studies of Treatment Devices for PAD Despite Being Dominant Minority Population Affected by PAD
Studies Evaluating Usage of Drug-Coated Balloon for PAD Include Disproportionate Amount of Women by One-Third Compared to Men
Analysis Shows 51% of PAD Cases Involve Women Despite Experiencing Less Severe Outcomes
Long Beach, Calif. – May 4, 2024 – New study findings underscore gaps in clinical trial representation of women and Hispanics for peripheral artery disease (PAD) and chronic limb-threatening ...
